Hyperphosphatemia

Hyperphosphatemia Slightly Reduces Calcimimetics’ Effects

Publish Date January 14, 2022

Study findings suggest serum phosphate is a negative modulator of calcium receptor activation.

Potassium Binder May Also Lower Phosphate Levels in CKD

Publish Date November 19, 2021

Patiromer may be another therapeutic option for patients with both hyperkalemia and hyperphosphatemia.

RCT Data Needed on Phosphate-Lowering Agents and NDD-CKD Outcomes

Publish Date October 21, 2021

Systematic reviews on this topic have largely been focused on patients receiving dialysis.

Phosphate Binder Dissatisfaction May Affect Patient Outcomes

Publish Date September 28, 2021

Dissatisfaction with taking phosphate binders may influence medication adherence and ultimately clinical outcomes, according to investigators.

FDA Wants Another Study Before Deciding on Tenapanor Approval

Publish Date August 16, 2021

Tenapanor inhibits the sodium/hydrogen exchanger 3 to control serum phosphorus in adults with CKD on dialysis.

Tenapanor Monotherapy May Reduce Phosphorus Levels in Patients on Dialysis

Publish Date August 4, 2021

Full results from the OPTIMIZE study, due to be completed in August 2021, are forthcoming.

Tenapanor Reduces Phosphate Binder Pill Burden in Hemodialysis

Publish Date July 20, 2021

Unlike phosphate binders, tenapanor decreases paracellular phosphate absorption in the intestine.

In-Center Nocturnal Hemodialysis May Improve HRQOL

Publish Date June 30, 2021

In a small Canadian study, investigators found that patients switched from conventional to in-center nocturnal hemodialysis experience improvements in various measures of health-related quality of life, especially mental health.

SHPT, Hyperphosphatemia Independently Linked With CKD Progression

Publish Date June 15, 2021

Investigators ruled out hyperphosphatemia and SHPT as confounders in each other’s association with CKD outcomes.

Non-Calcium Phosphate Binder May Not Further Reduce Cardiovascular Events

Publish Date June 3, 2021

Trial investigated lanthanum carbonate, which has been used worldwide to treat hyperphosphatemia and has been reported to delay vascular calcification.